Inhibition of CaMKII Does Not Attenuate Cardiac Hypertrophy in Mice with Dysfunctional Ryanodine Receptor

Asima Chakraborty¹*, Daniel A. Pasek¹, Tai-Qin Huang¹, Angela C. Gomez², Naohiro Yamaguchi², Mark E. Anderson³, Gerhard Meissner¹*

¹ Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC, United States of America, ² Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC, United States of America, ³ Division of Cardiovascular Medicine, Departments of Internal Medicine, and Molecular Physiology and Biophysics, University of Iowa, Iowa City, IA, United States of America

Abstract

In cardiac muscle, the release of calcium ions from the sarcoplasmic reticulum through ryanodine receptor ion channels (RyR2s) leads to muscle contraction. RyR2 is negatively regulated by calmodulin (CaM) and by phosphorylation of Ca²⁺/CaM-dependent protein kinase II (CaMKII). Substitution of three amino acid residues in the CaM binding domain of RyR2 (RyR2-W3587A/L3591D/F3603A, RyR2ADA) impairs inhibition of RyR2 by CaM and results in cardiac hypertrophy and early death of mice carrying the RyR2ADA mutation. To test the cellular function of CaMKII in cardiac hypertrophy, mutant mice were crossed with mice expressing the CaMKII inhibitory AC3-I peptide or the control AC3-C peptide in the myocardium. Inhibition of CaMKII by AC3-I modestly reduced CaMKII-dependent phosphorylation of RyR2 at Ser-2815 and markedly reduced CaMKII-dependent phosphorylation of SERCA2a regulatory subunit phospholamban at Thr-17. However, the average life span and heart-to-body weight ratio of RyR2ADA/ADA mice expressing the inhibitory peptide were not altered compared to control mice. In RyR2ADA/ADA homozygous mice, AC3-I did not alter cardiac morphology, enhance cardiac function, improve sarcoplasmic reticulum Ca²⁺ handling, or suppress the expression of genes implicated in cardiac remodeling. The results suggest that CaMKII was not an important factor for the rapid development of cardiac hypertrophy in RyR2ADA/ADA mice.

Introduction

In cardiac muscle, excitation-contraction coupling in response to an action potential initiates an influx of Ca²⁺ ions via dihydropyridine-sensitive L-type Ca²⁺ channels (Ca,1,2). This triggers the massive release of Ca²⁺ from an intracellular Ca²⁺-storage organelle, the sarcoplasmic reticulum (SR), by opening type 2 ryanodine receptor ion channels (RyR2s) [1]. The released Ca²⁺ causes muscle contraction. Sequestration of released Ca²⁺ back into the SR by an ATP-dependent Ca²⁺ pump (SERCA2a) leads to muscle relaxation.

Ca²⁺/calmodulin-dependent protein kinase II (CaMKII) regulates the cellular entry of activator Ca²⁺ through Ca,1,2 and thereby SR Ca²⁺ release via RyR2 [1–4]. Phosphorylation of SERCA2a regulatory protein phospholamban (PLN) at Ser-16 by protein kinase A and Thr-17 by CaMKII enhances SR Ca²⁺ sequestration [5]. Site directed mutagenesis of the predominant CaMKII phosphorylation site of RyR2 to mimic constitutively phosphorylated (RyR2-S2815D) and dephosphorylated (S2815A) channels, showed that CaMKII-dependent phosphorylation of RyR2 increases channel open probability and the risk of heart failure in mice following transverse aortic constriction [6,7].

Cardiac myocytes express two major CaMKI isoforms, γ and δ. Of these, CaMKIIγ has two splice variants, B and C. CaMKIIγδ has a nuclear localization signal and transcriptionally regulates signaling pathways in cardiac myopathies [8–10]. Overexpression of CaMKIIγδ or CaMKIIδC induced transactivating of myocyte enhancer factor 2 (MEF2)-dependent gene expression and up-regulation of hypertrophic marker genes [11]. Overexpression of cytosolic CaMKIIδC increased RyR2 and PLN phosphorylation, enhanced Ca²⁺ spark activity, and reduced SR Ca²⁺ content [11,12]. CaMKIIδ knockout mice had no major changes in ventricular structure and function [13,14]. However, after pressure overload induced by transaortic banding surgery, cardiac remodeling was reduced in CaMKIIδ deficient mice, which exhibited inhibition of RyR2 phosphorylation and reduced SR Ca²⁺ leak [13,14]. The results suggested that inhibition of CaMKII may limit the development of heart failure.

Citation: Chakraborty A, Pasek DA, Huang T-Q, Gomez AC, Yamaguchi N, et al. (2014) Inhibition of CaMKII Does Not Attenuate Cardiac Hypertrophy in Mice with Dysfunctional Ryanodine Receptor. PLoS ONE 9(8): e104338. doi:10.1371/journal.pone.0104338

Support of National Institutes of Health grants HL070250, HL079031, HL096652, HL113001 (to MEA), AR061030, American Heart Association grant 10SDG3500001 and National Science Foundation grant EPS0903795 (to NY), and HL073051 (to GM) are gratefully acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

¹ Email: meissner@med.unc.edu
² These authors contributed equally to this work.
³ Current address: Centre for Cellular & Molecular Biology, Council for Scientific and Industrial Research, Hyderabad - 500 007, Andhra Pradesh, India.
Based on the understanding of CaMKII as a pathological signaling molecule in cardiomyopathies, we asked whether an active strategy of chronic myocardial-targeted CaMKII inhibition could prevent or reduce cardiac hypertrophy in a mouse model (Ryr2<sup>ADA/ADA</sup> mice) with a well-defined mutation in RyR2. Ryr2<sup>ADA/ADA</sup> mice have three substituted amino acid residues in the calmodulin (CaM) binding domain of RyR2 (RyR2-W3587A/L3591D/F3603A, RyR2<sup>ADA</sup>) that disrupt its CaM inhibition at diastolic and systolic Ca<sup>2+</sup> concentrations and result in cardiac hypertrophy and the early death of Ryr2<sup>ADA/ADA</sup> mice [15]. While wild-type and Ryr2<sup>ADA/ADA</sup> mice had comparable CaMKII activities in 1-day old mice using an in vitro kinase assay [15], these studies did not rule out an in vivo procardiomyopathic role of CaMKII in Ryr2<sup>ADA/ADA</sup> mice. Additionally, in vitro measurements of CaMKII activity do not necessarily reflect the cellular activities in mice. Differences in Ca<sup>2+</sup> handling due to CaM impairment of RyR2 function and CaM distribution due to loss of RyR2 CaM binding may result in altered CaMKII activity in homozygous mutant hearts, which are difficult to assess in an in vitro assay.

To determine whether CaMKII inhibition could prevent or reduce cardiac hypertrophy, we crossed mutant mice with mice transgenically expressing CaMKII autocamtide 3 inhibitory peptide (AC3-I) or control peptide (AC3-C). Transgenic overexpression of AC3-I protected mouse hearts against pathological remodeling in response to myocardial infarction and β-adrenergic stimulation [16]. The present study shows that CaMKII inhibitory peptide AC3-I reduced phosphorylation of PLN at Thr-17 in Ryr2<sup>+/+</sup> and Ryr2<sup>ADA/ADA</sup> mice without significantly altering life span, cardiac morphology and performance, or markers of cardiac hypertrophy relative to mice expressing the control peptide. The findings suggest that the pathological effects of the RyR2<sup>ADA</sup> mutation are independent of myocardial CaMKII.

**Materials and Methods**

**Ethics Statement**

This study was carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the University of North Carolina at Chapel Hill Institutional Animal Care and Use Committee (10-062).

**Materials**

[<sup>3</sup>H]Ryanodine was obtained from Perkin Elmer Life Sciences. Protease and phosphatase inhibitor cocktails were from Sigma. Rabbit polyclonal antibody F9221 against RyR2 amino acid sequence 1372–1387 was produced by New England Peptide. Rabbit polyclonal antibody pRyR2 on Ser-2809 (A010-30AP) was from Badrilla (Leeds, UK). Rabbit polyclonal antibody to pRyR2 on Ser-2815 was the generous gift of Dr. Andrew Marks. Mouse monoclonal antibody PLN (A010-14) and rabbit polyclonal antibodies pPLN on Ser-16 (A010-12) and Thr-17 (A010-13) were from Badrilla (Leeds, UK). Rabbit polyclonal antibody pCaMKII on Thr-286 (ab32678) and two rabbit polyclonal antibodies against the conserved N-terminal (ab136400) and C-terminal (ab37999) regions of CaMKII<sub>G</sub> and CaMKII<sub>D</sub> were from Abcam. Comparable results were obtained using the two CaMKII
antibodies. Rabbit polyclonal antibodies protein kinase D (PKD) 
(#2052) and pPKD on S744/8 (#2054) and S916 (#2051) were 
from Cell Signaling Technology. Chemicals were from Sigma-
Aldrich unless specified otherwise.

Genetically modified mice

Ryr2^{+/ADA} mice [15] were mated with mice expressing the 
CaMKII inhibitory AC3-I peptide or the control AC3-C peptide 
[16]. Mice with AC3-I or AC3-C peptide expression were each 
backcrossed at least 5 times to 129Svev genetic background. Nine 
different genotypes of mice were obtained by crossing 
Ryr2^{+/+} mice expressing either of the two peptides according to Mendelian 
Law. Of these, the 4 genotypes investigated were Ryr2^{+/+} mice 
expressing AC3-I or AC3-C, and Ryr2^{ADA/ADA} mice expressing 
AC3-I or AC3-C.

Echocardiography

To determine left ventricular cardiac function, transthoracic M-
mode echocardiography was performed on restrained, unanesthe-
tized 10-day old mice, using the Vevo 2100 high resolution 
imaging system (VisualSonics) with 40 MHz probe [15]. Mice 
were restrained by taping down gently on a warmed board (Indus 
Industries for VisualSonics).

Morphological analysis

Hearts from 9–11 day old mice were fixed with 4% (w/v) 
paraformaldehyde in PBS (pH 7.4) and dehydrated using increas-

Table 1. Echocardiography of 10-day old mice double targeted for RyR2^{ADA} and AC3 peptides.

| Parameters | RyR2^{+/+} | RyR2^{+/+} | RyR2^{ADA/ADA} | RyR2^{ADA/ADA} |
|------------|------------|------------|----------------|----------------|
|            | AC3-C      | AC3-I      | AC3-C          | AC3-I          |
|            | (n = 8)    | (n = 6)    | (n = 8)        | (n = 6)        |
| LV/BW      | 0.142 ± 0.010 | 0.153 ± 0.016 | 0.267 ± 0.034a | 0.312 ± 0.042a |
| HR (bpm)   | 612 ± 26   | 613 ± 20   | 484 ± 14a      | 477 ± 18a      |
| LVEDD (mm) | 1.63 ± 0.10 | 1.58 ± 0.10 | 3.01 ± 0.27a   | 2.93 ± 0.19a   |
| LVESD (mm) | 0.59 ± 0.07 | 0.65 ± 0.11 | 2.52 ± 0.29a   | 2.38 ± 0.21a   |
| FS (%)     | 64.3 ± 3.4 | 59.4 ± 6.1 | 17.5 ± 2.2a    | 19.3 ± 1.9a    |
| IVSD (mm)  | 0.84 ± 0.07 | 0.89 ± 0.09 | 0.80 ± 0.04    | 0.70 ± 0.04    |
| IVSS (mm)  | 1.29 ± 0.07 | 1.29 ± 0.13 | 1.00 ± 0.05a   | 0.90 ± 0.05a   |
| LVPWD (mm) | 0.70 ± 0.06 | 0.72 ± 0.05 | 0.94 ± 0.12    | 0.78 ± 0.07    |
| LVPWS (mm) | 1.08 ± 0.07 | 1.09 ± 0.07 | 1.17 ± 0.11    | 0.99 ± 0.09    |
| EF(%)      | 92.8 ± 2.4 | 89.9 ± 2.1 | 38.1 ± 4.3a    | 44.1 ± 2.1a    |

LV/BW, left ventricular weight to body weight; HR, heart rate; bpm, beats/min; LVEDD, left ventricular end diastolic dimension; LVESD, left ventricular end systolic dimension; FS, fractional shortening (LVEDD - LVESD/LVEDD); IVSD, interventricular septum diastolic thickness; IVSS, interventricular septum systolic thickness; LVPWD, left ventricular posterior wall diastolic thickness; LVPWS, left ventricular posterior wall systolic thickness, EF, ejection fraction. Data are the mean ± SEM of number of mice shown in parenthesis.

*p<0.05 compared to Ryr2^{+/+}/AC3-C and Ryr2^{+/+}/AC3-I using one way ANOVA.

doi:10.1371/journal.pone.0104338.t001

Figure 2. Echocardiograms of wild-type and mutant hearts. Representative M-mode echocardiograms of 10-day old Ryr2^{+/+}/AC3-C (WC) and/AC3-I (WI) and Ryr2^{ADA/ADA}/AC3-C (HC) and/AC3-I (HI) mice are shown. Left ventricular end-diastolic (right arrows) and end-systolic (left arrows) dimensions are indicated.
doi:10.1371/journal.pone.0104338.g002
ing concentrations of ethanol in water [15]. Paraffin embedded hearts were sectioned to 6–9 μm thickness and stained as described [15].

Quantitative RT-PCR

Gene expression was measured by quantitative RT-PCR using the ABI Prism 7700 Sequence Detector (Applied Biosystems) [17]. RNA was isolated from left ventricles of 10-day-old mice using the ABI Prism 6700 Automated Nucleic Acid Workstation according to the manufacturer’s protocol. Primers and fluorogenic probes for β-myosin heavy chain (β-MHC), atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) were described [18]. Levels of gene expression as a percentage of Ryr2+/+/AC3-C were determined relative to β-actin.

Preparation of heart homogenates

Hearts of 10-day old mice were homogenized using a Tekmar Tissumizer for 3×7 s at a setting of 13,500 rpm in 20 mM imidazole, pH 7.0, 0.3 M sucrose, 0.15 M NaCl, protease and phosphatase inhibitor cocktails, 25 mM β-glycerophosphate, 5 mM NaF and 2.5 mM NaVO₄. Homogenates were stored in small aliquots at −80°C. Protein concentrations were determined using BCA assay.

Immunoblot analyses

Homogenates (20 μg protein/lane) were separated by SDS/PAGE and transferred to nitrocellulose membranes [19]. Membranes were blotted with 2% Advance blocking reagent (Amerham Biosciences) in 0.5% Tween 20, Tris buffered saline (TBS), pH 7.4 at 24°C and probed with primary antibodies and secondary peroxidase-conjugated IgG antibody. Immunoblots were developed using enhanced chemiluminescence and quantified using ImageQuantTL Analysis Software.

[3H]Ryanodine binding

Specific binding of [3H]ryanodine to RyRs was measured to determine the number of RyR high affinity binding sites [20]. Cardiac muscle homogenates were incubated for 4–5 h at 24°C with a near saturating concentration of 20 nM [3H]ryanodine in 20 mM imidazole, pH 7.0, 0.6 M KCl, 0.1 mM Ca²⁺, and protease inhibitors as described [15]. Nonspecific binding was determined using 1000-fold excess of unlabeled ryanodine.

45Ca²⁺ uptake rate

ATP-dependent 45Ca²⁺ uptake rates by homogenates were determined using a filtration assay as described [15]. 45Ca²⁺ uptake rates were determined in presence of 6 μM KN93, a CaMKII specific inhibitor.
Data were obtained analyzing proteins from 4–6 hearts of each genotype and are the mean ± SEM of 15–16 (B) and 5–7 (C) determinations using two way ANOVA. None of the differences were significant.

doi:10.1371/journal.pone.0104338.g004

Data analysis

Results are expressed as mean ± SEM. Differences between samples were analyzed using one or two way ANOVA followed by Tukey test.

Results

*Ryr2*^ADA^ mutant mice expressing the CaMKII inhibitory peptide AC3-I or control peptide AC3-C were mated to obtain *Ryr2*^+/+^ and *Ryr2*^ADA/ADA^ mice expressing AC3-I or AC3-C. Sixteen *Ryr2*^ADA/ADA^ mice expressing AC3-I died 12 to 58 days after birth compared with 16 mutant mice expressing the control peptide that died 14 to 35 days after birth (Fig. 1). Mean lifetimes after birth compared with 16 mutant mice expressing the control peptide were 28.1 ± 3.0 and 26.4 ± 1.6 days for *Ryr2*^+/+^ and *Ryr2*^ADA/ADA^ mice expressing the inhibitory and control peptides, respectively. Thus, there was no significant difference between wild-type or mutant mice expressing AC3-C or AC3-I (Table 1). However, there was no significant difference between wild-type or mutant mice expressing AC3-C or AC3-I (Table 1). The data suggest that inhibition of CaMKII by AC3-I did not improve cardiac performance of *Ryr2*^ADA/ADA^ mice compared to mutant mice expressing the control peptide.

Morphological analysis confirmed the generation of hypertrophied hearts and dilated left ventricle chambers in *Ryr2*^ADA/ADA^ mice with control or inhibitory peptides (Fig. 3A). Consistent with left ventricle/body weight ratio (Table 1), there were no noticeable differences in heart size between AC3-C and AC3-I groups. Heart sections from 5 wild-type and 8 mutant mice expressing either AC3-C or AC3-I were stained with TRITC-conjugated wheat germ agglutinin and cellular cross-sectional areas were determined. No significant differences were observed between *Ryr2*^ADA/ADA^ hearts expressing AC3-C or AC3-I (Fig. 3B). In contrast, *Ryr2*^ADA/ADA^ hearts were significantly increased compared to *Ryr2*^+/+^ hearts (Fig. 3B).

(RVESL) were significantly increased in *Ryr2*^ADA/ADA^ mice compared with *Ryr2*^+/+^ mice in the absence of the peptides (Fig. 2, Table 1). Fractional shortening (FS) calculated from the two above parameters and ejection fraction (EF) were significantly reduced in mutant mice. However, there was no significant difference between wild-type or mutant mice expressing AC3-C or AC3-I (Table 1). The data suggest that inhibition of CaMKII by AC3-I did not improve cardiac performance of *Ryr2*^ADA/ADA^ mice compared to mutant mice expressing the control peptide.

Immunoblot analysis showed that similar CaMKII protein levels were present in heart homogenates of wild-type and mutant mice expressing AC3-C or AC3-I peptides (Figs. 4A and B). We
also determined autophosphorylation of CaMKII on Thr-286, which switches the kinase from a Ca\(^{2+}\)/CaM-dependent to Ca\(^{2+}\)/CaM-independent state. In agreement with a previous study [16], autophosphorylation of CaMKII increased (not significant) in wild-type and mutant mice expressing AC3-I compared to mice expressing AC3-C (Figs. 4A and C). However, increased pCaM-KII-T286/CaMKII ratio was not expected to enhance CaMKII activity in AC3-I mice, because autophosphorylated CaMKII is inhibited by AC3-I [16].

To verify that AC3-I inhibited CaMKII activity in AC3-I mice, phosphorylation levels of RyR2 and phospholamban (PLN) were determined by immunoblot analysis. RyR2 is phosphorylated at Ser-2809 by protein kinase A (PKA) and at Ser-2815 by CaMKII [21,22]. In agreement with previous studies [15], total RyR2 protein expression was reduced by 60% in homozygous mice compared to WT expressing inhibitory and control AC3 peptides (Fig. 5). In hearts expressing the control peptide, increased pRyR2-S2809/RyR2 and pRyR2-S2815/RyR2 ratios were observed in mutant hearts compared with total RyR2 protein. AC3-I reduced (not significant) pRyR2-S2815/RyR2 phosphorylation ratios in wild-type and mutant hearts compared with hearts expressing the control peptide. One caveat is that we could not distinguish between mice carrying transgenes of AC3-I and AC3-C in one allele or both. It is therefore conceivable that in mice expressing fewer copies, the AC3-I concentration was suboptimal in inhibiting CaMKII associated with RyR2 [22].

PLN has two physiologically relevant phosphorylation sites, Ser-16 phosphorylated by PKA and Thr-17 phosphorylated by CaMKII [5]. Immunoblots in Fig. 6 show similar total PLN protein levels in RyR2\(^{+/+}\) and RyR2ADA/ADA hearts harboring AC3-C or AC3-I peptides. Among PLN, pPLN-S16/PLN and pPLN-T17/PLN panels a number of significant changes were observed. Comparable pPLN-T17/PLN phosphorylation ratios were present in RyR2\(^{+/+}\) and RyR2ADA/ADA hearts expressing the control peptide. In contrast, phosphorylation ratios of pPLN-T17/PLN decreased by 75% in RyR2\(^{+/+}\) hearts compared to an 85% decrease in RyR2ADA/ADA hearts expressing the inhibitory peptide. This suggests that AC3-I inhibited CaMKII activity in RyR2\(^{+/+}\) and RyR2ADA/ADA hearts.

Protein kinase D (PKD) is a member of the CaMK superfamily [23] and has been reported to be inhibited by AC3-I [14]. Fig. 7 compares protein levels of PKD and phosphorylation of PKD on Ser-744/Ser-748 and Ser-916 in wild-type and mutant hearts expressing AC3-I or AC3-C peptides. Similar PKD protein levels (Fig. 7B) and pPKD/PKD phosphorylation ratios (Figs. 7C and D) were observed in hearts of wild-type and RyR2ADA/ADA mice.

Figure 6. PLN phosphorylation on Ser-16 and Thr-17 in heart homogenates. (A) Immunoblots of PLN, pPLN-S16 and pPLN-Thr17 of heart homogenates from 10-day old RyR2\(^{+/+}\)/AC3-C (WC) and AC3-I (WI) and RyR2ADA/ADA/AC3-C (HC) and AC3-I (HI) mice. Glycerinaldehyde-3 phosphate dehydrogenase was the loading control. (B) Intensity of PLN protein bands normalized for RyR2\(^{+/+}\)/AC3-C protein band intensities. (C and D) pPLN/PLN phosphorylation ratios were the mean ± SEM of 10–12 determinations using two way ANOVA. *p<0.05 compared to WC-T17 and HC-T17, **p<0.05 compared to WI-S16, ***p<0.05 compared to WC-S16, ****p<0.05 compared to HI-T17, *****p<0.05 compared to HC-S16.

doi:10.1371/journal.pone.0104338.g006
We tested whether AC3-I altered the expression of several genes linked to cardiac hypertrophy. In agreement with our previous report [15], quantitative RT-PCR showed that mRNA levels of β-MHC, ANP and BNP increased in the left ventricle of 10-day old RyR2ADA/ADA mice compared to RyR2+/+ mice (Fig. 8). There were no marked differences in the expression levels of these genes in RyR2+/+ hearts expressing AC3-I or AC3-C. Similarly, the expression levels of β-MHC, ANP and BNP were not significantly altered in RyR2ADA/ADA hearts expressing AC3-I or AC3-C.

We then asked whether AC3-I altered SR Ca2+ handling of RyR2+/+ and RyR2ADA/ADA mice. Bmax values of [3H]ryanodine binding, which are a measure of RyR2 protein levels, and 45Ca2+ uptake rates, which reflect SR Ca2+ pump activity, were determined. The significantly reduced Bmax of [3H]ryanodine binding in RyR2ADA/ADA hearts compared to RyR2+/+ [15] was not altered further by AC3-I or AC3-C in RyR2+/+ and RyR2ADA/ADA mice (Fig. 9A). In mutant mice, reduced 45Ca2+ uptake rates were reduced to a level similar in RyR2ADA/ADA hearts expressing AC3-C or AC3-I compared to RyR2+/+ hearts expressing AC3-I or AC3-C peptides. SR Ca2+ uptake was likely not reduced by AC3-I because PLN-S16 phosphorylation, which was less affected by AC3-I compared to PLN-17 (Fig. 6), was sufficient to mediate a maximal β-agonist-mediated cardiac response in perfused hearts [24]. To compensate for the lower AC3-I concentration due to sample dilution, experiments were done in the presence of CaMKII inhibitor KN93. Taken together, the results suggest that the CaMKII inhibitory peptide did not improve depressed cardiac Ca2+ handling of RyR2ADA/ADA mice.

**Discussion**

CaMKII and CaM modulate cardiac muscle function by regulating multiple ion channels and transport systems [2]. We previously showed the physiological importance of an interaction between RyR2 and CaM in cardiac muscle by generating mice expressing mutant RyR2 (RyR2ADA) with disrupted CaM regulation [15]. RyR2ADA/ADA mice develop cardiac hypertrophy by postnatal day 1 and die within 2 weeks after birth. Impaired CaM regulation of RyR2 resulted in upregulation of ERK/p90RSK signaling and reduced GSK-3β activity in E16.5 heart homogenates [19]. Calcineurin A-β and class II HDAC/MEF2 signaling pathways, which have a critical role in pathological hypertrophy regulated by CaMKII [25], were up-regulated in 1-day and 10-day old but not E16.5 RyR2ADA/ADA hearts. In the present study, pRyR2-S2815 phosphorylation was not increased in the mutant mice. The result suggests that CaMKII-mediated RyR2 phosphorylation does not have an essential role in the RyR2ADA/ADA phenotype.

Heart failure is a major public health problem without adequate therapies. Since CaMKII has emerged as a procardiomyopathic...
We generated and characterized a second mutant mouse model that wild-type and mutant mice were more resistant than wild-type mice during myocardial infarction. In an in vivo study that addresses PKD activity. Protein kinase D (PKD), a member of the CaMK superfamily [23], has been reported to be inhibited by AC3-I [14]. While a direct interaction with RyR2 has not been established, PKD, like CaMKII, phosphorylates class II histone deacetylases, which triggers their nuclear export, thereby regulating transcription and promoting cardiac remodeling [14,38,39]. Immunoblots did not show significant differences in total PKD, pPKD-S744/S748 and PKD-S916 protein levels between 10-day old wild-type and mutant mice expressing AC3 control or inhibitory peptides (Fig. 7). However, phosphorylation at these sites does not necessarily reflect PDK activity in mutant and wild-type hearts. PKD binds diacylglycerol, which is formed by a variety of cellular stimuli, inducing cellular redistribution of the enzyme, and potentially altering PKD activity [23,40]. Therefore, physiological relevance of in vitro measurements is uncertain, using the isolated form of the enzyme. To our knowledge there are no unique targets for PKD that could have been used to assess in vivo PKD activity.

In conclusion, the results suggest that CaMKII does not have an essential role in the rapid development of cardiac hypertrophy and early death of mutant mice impaired in CaM regulation of RyR2 at diastolic and systolic Ca\(^{2+}\) concentrations. Although RyR2 mutations that impair CaM regulation in cardiac pathologies have not yet been identified, our studies should help to understand the role of RyR2 regulation by CaM and CaMKII in cardiac hypertrophy and heart failure in humans.
Author Contributions
Conceived and designed the experiments: AC DAP NY MEA GM. Performed the experiments: AC DAP TQH ACG NY. Analyzed the data: MEA.

References
1. Bers DM (2002) Cardiac excitation-contraction coupling. Nature 415: 198–205.
2. Anderson ME, Brown JH, Bers DM (2011) CaMKII in myocardial hypertrophy and heart failure. J Mol Cell Cardiol 51: 468–473.
3. Anderson ME (2009) Calmodulin kinase II-type calcium channels: a recipe for arrhythmias? Trends Cardiovasc Med 14: 151–162.
4. Halling DB, Aracena-Parks P, Hamilton SL (2005) Regulation of voltage-gated Ca2+ channels by calmodulin. Sci STKE 20: re15.
5. Mattiazzi A, Kramias EG (2011) CaMKII regulation of phospholamban and SR Ca2+ load. Heart Rhythm 8: 765–787.
6. van Oort RJ, Mcauley MD, Dixit SS, Pereira L, Yang Y, et al. (2010) Ryanodine receptor phosphorylation by calcium/calmodulin-dependent protein kinase II promotes life-threatening ventricular arrhythmias in mice with heart failure. Circulation 122: 2669–2679.
7. Respress JL, van Oort RJ, Li N, Rollin N, Dixit SS, et al. (2012) Role of RyR2 phosphorylation at S2814 during heart failure progression. Circ Res 110: 1474–1483.
8. Bossuyt, J, Helmestadter K, Wu X, Clements-Jewery, H, Haworth RS, et al. (2008) Ca2+/calmodulin-dependent protein kinase II(delta) and protein kinase D overexpression reinforce the histone deacetylase 5 redistribution in heart failure. Circ Res 102: 695–702.
9. Zhang T, Johnson EN, Gu Y, Morissette MR, Sah VP, et al. (2002) The cardiac-specific nuclear delta(B) isoform of Ca2+/calmodulin-dependent protein kinase II induces hypertrophy and dilated cardiomyopathy associated with increased protein phosphatase 2A activity. J Biol Chem 277: 1261–1267.
10. Li B, Dedman JR, Kaertelz MA (2006) Nuclear Ca2+/calmodulin-dependent protein kinase II in the murine heart. Biochim Biophys Acta 1763: 695–721.
11. Zhang T, Kohilaas M, Backs J, Mishra S, Phillips W, et al. (2007) CaMKII delta isoforms differentially affect cardiac handling but similarly regulate HDAC. J Biol Chem 282: 55078–55087.
12. Maier LS, Bers DM (2007) Role of Ca2+/calmodulin-dependent protein kinase (CaMK) in excitation-contraction coupling in the heart. Cardiovasc Res 75: 631–640.
13. Ling H, Zhang T, Pereira I, Means CK, Cheng H, et al. (2009) Requirement for Ca2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice. J Clin Invest 119: 1230–1240.
14. Backs J, Backs T, Neef S, Kreusser MM, Lehmann LH, et al. (2009) The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proc Natl Acad Sci USA 106: 2342–2347.
15. Yamasuchi N, Tachibana N, Xu L, Smithies O, Meissner G (2007) Early cardiac hypertrophy in mice with impaired calmodulin regulation of cardiac muscle Ca2+ release channel. J Clin Invest 117: 1344–1353.
16. Zhang R, Khoo MS, Wu Y, Yang Y, Gruter CF, et al. (2005) Calmodulin kinase II inhibition protects against structural heart disease. Nat Med 11: 409–417.
17. Kim HS, Lee G, John SWM, Maeda N, Smithies O (2002) Molecular phenotyping for analyzing subtle genetic effects in mice: Application to an angiotensinogen gene titration. Proc Natl Acad Sci USA 99: 4692–4697.
18. Caron KM, James LR, Kim HS, Knowles J, Uhlir R, et al. (2004) Cardiac hypertrophy and sudden death in mice with a genetically clamped renin transgene. Proc Natl Acad Sci U S A 101: 3106–3111.
19. Yamasuchi N, Chakraborthy A, Pasek DA, Melkennis JD, Meissner G (2011) Dysfunctional ryanodine receptor and cardiac hypertrophy: role of signaling molecules. Am J Physiol 300: H2187–H2195.
20. Suto JL, Airey JA, Welch W, Ruesl L (1997) The pharmacology of ryanodine and related compounds. Pharmacol Rev 49: 53–98.
21. Witcher DR, Kovacs RJ, Schulman H, Cefalì DC, Jones LR (1991) Unique phosphorylation site on the cardiac ryanodine receptor regulates calcium channel activity. J Biol Chem 266: 11144–11152.
22. Wehrens XH, Lehrnt SE, Reiken SR, Marks AR (2004) Ca2+/calmodulin-dependent protein kinase II phosphorylation regulates the cardiac ryanodine receptor. Circ Res 94: e61–70.
23. Rozengurt E, Roy O, Waldron RT (2003) Protein kinase D signaling. J Biol Chem 278: 13205–13208.
24. Chu G, Lexter JV, Young KB, Luo W, Zhai J, et al. (2000) A single site (Ser16) phosphorylation in phospholamban is sufficient in mediating its maximal cardiac responses to beta-agonists. J Biol Chem 275: 38930–38935.
25. Backs J, Song K, Becprosvannaya S, Chang S, Ozen EN (2006) CaM kinase II selectively signals to histone deacetylate 4 during cardiomyocyte hypertrophy. J Clin Invest 116: 1033–1046.
26. Swannamnan FD, Purohit A, Handl T, Anderson ME (2012) Calmodulin-dependent protein kinase II: Linking heart failure and arrhythmias. Circ Res 110: 1661–1677.
27. Li N, Wang T, Wang W, Cutler MJ, Wang Q, et al. (2012) Inhibition of CaMKII phosphorylation of RyR2 prevents induction of atrial fibrillation in FKBP12.6 knockout mice. Circ Res 110: 465–470.
28. Mcauley MD, Wehrens XH (2011) Ryanodine receptor phosphorylation, calcium/calmodulin-dependent protein kinase II, and life-threatening ventricular arrhythmias. Trends Cardiovasc Med 21: 48–51.
29. Soussia S, Flachskul N, Schostola H, Ort KR, Neef S, et al. (2010) Inhibition of elevated Ca2+/calmodulin-dependent protein kinase II improves contractility in human failing myocardium. Circ Res 107: 1150–1161.
30. Rokita AG, Anderson ME (2012) New therapeutic targets in cardiology: arrhythmias and Ca2+/calmodulin-dependent kinase II. Circulation 126: 2125–2139.
31. Fischer TH, Herting J, Tirolinon T, Renner A, Neef S, et al. (2013) Ca2+/calmodulin-dependent protein kinase II and protein kinase A differentially regulate sarcoplasmic reticulum Ca2+ leak in human cardiac pathology. Circulation 125: 970–981.
32. Saiti M, Becerra R, Valverde CA, Kaertsel MA, Dedman JR, et al. (2011) Calcium-calmodulin dependent protein kinase II (CaMKII): a main signal responsible for early reperfusion arrhythmias. J Mol Cell Cardiol 49: 936–946.
33. Khoo MS, Kannankeril PJ, Li J, Zhang R, Kupershmidt S, et al. (2005) Calmodulin kinase II activity is required for normal atrioventricular nodal conduction. Heart Rhythm 2: 634–640.
34. Singh MV, Kapous A, Huggins L, Kutscheik W, Thurman JM, et al. (2009) Ca2+/calmodulin-dependent kinase II triggers cell membrane injury by inducing complement factor B gene expression in the mouse heart. J Clin Invest 119: 986–996.
35. Yang Y, Zhu WZ, Joiner ML, Zhang R, Oddis CV, et al. (2006) Calmodulin kinase II inhibition protects against myocardial cell apoptosis in vivo. Am J Physiol 291: H3065–H3075.
36. Yamasuchi N, Chakraborty A, Huang TQ, Xu L, Gomez AC, et al. (2013) Cardiac hypertrophy associated with impaired regulation of cardiac ryanodine receptor by calmodulin and S100A1. Amer J Physiol 305: H186–H194.
37. Zhang T, Brown JH (2004) Role of Ca2+/calmodulin-dependent protein kinase II in cardiac hypertrophy and heart failure. Cardiovasc Res 63: 476–486.
38. Vega KB, Harrison BC, Meadow E, Roberts CR, Papst PJ, et al. (2004) Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol Cell Biol 24: 8374–8385.
39. Bossuyt J, Helmestadter K, Wu X, Clements-Jewery H, Haworth RS, et al. (2008) Ca2+/calmodulin-dependent protein kinase II delta and protein kinase D overexpression reinforce the histone deacetylase 5 redistribution in heart failure. Circ Res 102: 695–702.
40. Steinberg SF (2012) Regulation of protein kinase PKD1 activity. Mol Pharmacol 81: 204–291.